HM Pharma
ActiveSummary
HM Pharma has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €354,554 and a net result of €67,980. Equity is growing by about 34% per year across the filed financial years. Its solvency ranks better than 48% of 459 sector peers (NACE 47, financial year 2026). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2027, expected by
2026
28-09
NBB filing
Annual accounts filed
financial year 2026 · abbreviated format
2025
14-10
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
31-03
Financial
Highest result from 2022 to 2026net €73,689 ▲2.5%
Operating result €102,236, net result €73,689, both a record.
2024
15-10
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
31-03
Financial
Equity above €200,000equity €212,885 ▲51%
A profit in every financial year since 2022 builds equity to €212,885.
2023
09-10
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
31-03
Financial
Equity above €100,000equity €141,008 ▲102%
A profit in every financial year since 2022 builds equity to €141,008.
2022
10-10
NBB filing
Annual accounts filed
financial year 2022 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.